Ceftazidime-Avibactam Susceptibility Breakpoints Against Enterobacteriaceae and Pseudomonas aeruginosa.

Nichols, Wright W, Stone, Gregory G, Newell, Paul, Broadhurst, Helen, Wardman, Angela, MacPherson, Merran, Yates, Katrina, Riccobene, Todd, Critchley, Ian A and Das, Shampa ORCID: 0000-0002-2540-4816 (2018) Ceftazidime-Avibactam Susceptibility Breakpoints Against Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 62 (11). e02590-e02517.

Text
AAC CAZ-AVI breakpoints author accepted.pdf - Author Accepted Manuscript
Download (373kB)

Official URL: https://aac.asm.org/content/62/11/e02590-17

Abstract

Clinical susceptibility breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa for the ceftazidime-avibactam dosage regimen of 2000-500 mg every 8 hours (q8h) by 2-h intravenous infusion (adjusted for renal function) have been established by the FDA, CLSI and EUCAST as susceptible, MIC ≤8 mg/L, and resistant, MIC >8 mg/L. The key supportive data from PK/PD analyses, in vitro surveillance including molecular understanding of relevant resistance mechanisms, and efficacy in regulatory clinical trials, are collated and analyzed here.

Item Type:	Article
Uncontrolled Keywords:	MIC breakpoints, ceftazidime-avibactam
Depositing User:	Symplectic Admin
Date Deposited:	02 Nov 2018 09:01
Last Modified:	19 Jan 2023 01:13
DOI:	10.1128/aac.02590-17
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3028281